JP2021535149A5 - - Google Patents
Info
- Publication number
- JP2021535149A5 JP2021535149A5 JP2021510824A JP2021510824A JP2021535149A5 JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5 JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- her2 bispecific
- pharmaceutical product
- system inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18191041.5 | 2018-08-27 | ||
| EP18191041 | 2018-08-27 | ||
| PCT/EP2019/072754 WO2020043683A1 (en) | 2018-08-27 | 2019-08-27 | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535149A JP2021535149A (ja) | 2021-12-16 |
| JP2021535149A5 true JP2021535149A5 (enExample) | 2022-08-12 |
| JP7459058B2 JP7459058B2 (ja) | 2024-04-01 |
Family
ID=63578931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510824A Active JP7459058B2 (ja) | 2018-08-27 | 2019-08-27 | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210246219A1 (enExample) |
| EP (1) | EP3843849A1 (enExample) |
| JP (1) | JP7459058B2 (enExample) |
| KR (1) | KR20210052468A (enExample) |
| CN (1) | CN112955221A (enExample) |
| AU (1) | AU2019328632A1 (enExample) |
| CA (1) | CA3106881A1 (enExample) |
| WO (1) | WO2020043683A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| EP4213946A1 (en) * | 2020-09-18 | 2023-07-26 | Pieris Pharmaceuticals GmbH | Biomarker methods and uses |
| JP7875865B2 (ja) * | 2021-01-25 | 2026-06-18 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| US20250339523A1 (en) * | 2022-01-25 | 2025-11-06 | Merus N.V. | Combination therapy for the treatment of cancer |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| RU2692773C2 (ru) * | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| DK3049441T3 (da) | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| RU2727165C2 (ru) * | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| RU2693661C2 (ru) | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
-
2019
- 2019-08-27 AU AU2019328632A patent/AU2019328632A1/en not_active Abandoned
- 2019-08-27 CA CA3106881A patent/CA3106881A1/en active Pending
- 2019-08-27 WO PCT/EP2019/072754 patent/WO2020043683A1/en not_active Ceased
- 2019-08-27 KR KR1020217007565A patent/KR20210052468A/ko not_active Ceased
- 2019-08-27 US US17/271,149 patent/US20210246219A1/en not_active Abandoned
- 2019-08-27 EP EP19756382.8A patent/EP3843849A1/en not_active Withdrawn
- 2019-08-27 CN CN201980071320.7A patent/CN112955221A/zh active Pending
- 2019-08-27 JP JP2021510824A patent/JP7459058B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Poletto et al. | Treatment strategies for patients with diffuse large B-cell lymphoma | |
| Choi et al. | T-cell agonists in cancer immunotherapy | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Vacchelli et al. | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Cultrera et al. | Diffuse large B-cell lymphoma: current strategies and future directions | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2022532490A5 (enExample) | ||
| KR102786010B1 (ko) | 조합 및 이의 용도 | |
| JP2021525735A5 (enExample) | ||
| JP2024505556A (ja) | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 | |
| JP2023536655A5 (enExample) | ||
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JP2024167261A (ja) | 抗原結合タンパク質 | |
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| WO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| Forero-Torres et al. | Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib/II dose-escalation study | |
| US20240166747A1 (en) | Antigen binding proteins and combinations thereof | |
| Deligne et al. | The vaccinal effect of monoclonal antibodies in cancer therapy | |
| Guo et al. | immunomodulatory drugs in |